公开(公告)号：US20240000789A1

公开(公告)日：2024-01-04

申请号：US17998391

申请日：2021-05-11

申请人： NOVARTIS AG

发明人： Giordano Caponigro ,  Vesselina Cooke ,  Uz Martin Stammberger ,  Darrin Stuart

IPC分类号： A61K31/5377 ,  A61K31/4965 ,  A61K31/519 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K31/5377 ,  A61K31/4965 ,  A61P35/04 ,  A61P35/00 ,  A61K31/519

摘要： The present invention provides a pharmaceutical combination comprising a CRAF inhibitor in combination with (i) an ERK inhibitor or (ii) a MEK inhibitor or (iii) a CDK4/6 inhibitor, each as defined herein, or independently in each case a pharmaceutically acceptable salt thereof, for use in the treatment of NRAS-mutant melanoma and in the treatment of BRAF-mutant melanoma. wherein the melanoma may be unresectable and/or metastatic melanoma.